A glycopeptide request is not defined by the peptide sequence plus a glycan name. The buyer must specify monosaccharide composition, branching, linkage, anomeric configuration and attachment site. When qualifying a custom glycopeptide synthesis service, I also ask how the supplier separates the target from positional isomers, partially assembled glycans and non-glycosylated peptide.
Draw the complete target structure
Use a structure or controlled glycan notation rather than terms such as “sialylated” or “complex glycan.” For N-linked constructs, define the modified asparagine and the exact glycan. For O-linked material, state serine or threonine position and alpha or beta linkage where relevant. Include peptide termini, disulfides and every additional modification.
A correct total composition does not prove correct linkage or branching. The quotation and COA should reference the same structure version.
Select a realistic synthetic route
Shorter defined glycopeptides may be assembled using glycosylated amino-acid building blocks during solid-phase synthesis. Larger glycans or longer sequences may require convergent ligation, enzymatic remodeling or a chemoenzymatic route. Each route creates different impurities and scale limitations.
Ask the supplier to identify which steps are chemical and which are enzymatic. Enzyme lot, donor substrate and reaction endpoint belong in the batch record when they affect glycoform distribution.
Purification must resolve more than peptide deletions
Glycopeptides can contain deletion sequences, aglycone peptide, truncated glycans, anomers and positional isomers. Reversed-phase HPLC may separate some species poorly because the glycan changes hydrophilicity without adding a strong UV chromophore. HILIC, ion-exchange or other orthogonal chromatography may be useful.
Review detector choice and recovery. UV area at a peptide wavelength can underrepresent carbohydrate-related impurities, while MS signal intensity is not automatically quantitative across glycoforms.
Mass confirms composition, not every structural detail
Accurate intact mass supports the expected composition. Tandem MS can show glycan fragments and peptide backbone coverage, but labile glycosidic bonds may fragment before the attachment site is fully localized. Exoglycosidase digestion, NMR or comparison with standards can strengthen difficult linkage assignments.
Require the report to distinguish confirmed structure from an assignment consistent with mass. A database match alone is not structural proof.
Content and vial delivery need a separate method
Gross lyophilized weight includes counterion, water and residual salts. Amino-acid analysis may support peptide-equivalent content but does not by itself quantify glycan occupancy. Define whether the delivered amount refers to complete glycopeptide mass or peptide equivalent.
Scale-up can shift the glycoform profile
Ligation concentration, enzyme ratio, purification load and drying conditions change with scale. Use a feasibility lot and lock critical reagents before bulk production. Compare full chromatographic and MS profiles, not only main-peak purity.
- Complete glycan structure, linkage and peptide site.
- Route description and critical reagent traceability.
- Orthogonal purity and identity methods.
- Non-glycosylated and truncated-glycan limits.
- Content basis, counterion, storage and fill.
Can LC-MS alone prove a glycopeptide structure? It can provide strong composition and fragmentation evidence, but some linkage and positional questions require orthogonal data. Send the exact structure, analytical use, scale and acceptable heterogeneity with the RFQ so the supplier can propose a defensible route and QC package.